{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:20:44Z","timestamp":1740144044947,"version":"3.37.3"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:00:00Z","timestamp":1604361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:00:00Z","timestamp":1604361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi del Piemonte Orientale Amedeo Avogrado"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40256-020-00446-6","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T18:02:43Z","timestamp":1604426563000},"page":"559-570","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Questions and Answers on Practical Thrombotic Issues in SARS-CoV-2 Infection: A Guidance Document from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology"],"prefix":"10.1007","volume":"20","author":[{"name":"the Italian Study Group on Atherosclerosis, Thrombosis, Vascular Biology","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5404-3968","authenticated-orcid":false,"given":"Giuseppe","family":"Patti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Lio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Cavallari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felice","family":"Gragnano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Letizia","family":"Riva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Calabr\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Di Pasquale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Pengo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Rubboli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,3]]},"reference":[{"issue":"5","key":"446_CR1","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00392-020-01626-9","volume":"109","author":"B Li","year":"2020","unstructured":"Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531\u20138.","journal-title":"Clin Res Cardiol"},{"key":"446_CR2","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893\u2013962.","journal-title":"Eur Heart J"},{"issue":"2 Suppl","key":"446_CR3","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","volume":"141","author":"C Kearon","year":"2012","unstructured":"Kearon C, Akl EA, Camerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e419S\u2013494S.","journal-title":"Chest"},{"key":"446_CR4","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s11239-018-1760-9","volume":"47","author":"AL Porter","year":"2019","unstructured":"Porter AL, Margolis AR, Staresinic CE, et al. Feasibility and safety of a 12week INR follow-up protocol over 2 years in an anticoagulation clinic: a single-arm prospective cohort study. J Thromb Thrombolysis. 2019;47:200\u20138.","journal-title":"J Thromb Thrombolysis"},{"key":"446_CR5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1751-553X.2007.00998.x","volume":"31","author":"W Plesch","year":"2009","unstructured":"Plesch W, van den Besselaar AM. Validation of the international normalized ratio (INR) in a new point-of-care system designed for home monitoring of oral anticoagulation therapy. Int J Lab Hematol. 2009;31:20\u20135.","journal-title":"Int J Lab Hematol"},{"key":"446_CR6","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955\u201362.","journal-title":"Lancet"},{"key":"446_CR7","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/phar.1344","volume":"33","author":"S Meyer","year":"2013","unstructured":"Meyer S, Frei CR, Kelly RD. Impact of a new method of warfarin management on patient satisfaction, time and cost. Pharmacotherapy. 2013;33:1147\u201355.","journal-title":"Pharmacotherapy"},{"key":"446_CR8","first-page":"1621","volume":"91","author":"I Mah\u00e9","year":"2006","unstructured":"Mah\u00e9 I, Bertrand N, Drouet L, et al. Interaction between paracetamol and warfarin in patients: a double-blind, placebo-controlled, randomized study. Haematologica. 2006;91:1621\u20137.","journal-title":"Haematologica"},{"key":"446_CR9","volume-title":"ESC guidance for the diagnosis and management of CV disease during the COVID-19 pandemic","author":"European Society of Cardiology","year":"2020","unstructured":"European Society of Cardiology. ESC guidance for the diagnosis and management of CV disease during the COVID-19 pandemic. Bruxelles: European Society of Cardiology; 2020."},{"key":"446_CR10","doi-asserted-by":"crossref","unstructured":"Misra S, Nath M, Hadda V, Vibha D. Efficacy of various treatment modalities for nCOV-2019: a systematic review and meta-analysis. Eur J Clin Invest. 2020;e13383.","DOI":"10.1111\/eci.13383"},{"key":"446_CR11","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/1744666X.2020.1792778","volume":"16","author":"SE Sattui","year":"2020","unstructured":"Sattui SE, Liew JW, Graef ER, et al. Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. Expert Rev Clin Immunol. 2020;16:659\u201366.","journal-title":"Expert Rev Clin Immunol."},{"key":"446_CR12","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1128\/AAC.03011-14","volume":"58","author":"AH de Wilde","year":"2014","unstructured":"de Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014;58:4875\u201384.","journal-title":"Antimicrob Agents Chemother"},{"key":"446_CR13","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","volume":"212","author":"JF Chan","year":"2015","unstructured":"Chan JF, Yao Y, Yeung ML, et al. Treatment with lopinavir\/ritonavir or interferon-\u03b21b improves outcome of MERSCoV infection in a nonhuman primate model of common marmoset. J Infect Dis. 2015;212:1904\u201313.","journal-title":"J Infect Dis"},{"key":"446_CR14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13063-017-2427-0","volume":"19","author":"YM Arabi","year":"2018","unstructured":"Arabi YM, Alothman A, Balkhy HH, et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-\u03b21b (MIRACLE trial): study protocol for a randomized controlled trial. Trials. 2018;19:81.","journal-title":"Trials"},{"key":"446_CR15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jhin.2018.09.005","volume":"101","author":"SY Park","year":"2019","unstructured":"Park SY, Lee JS, Son JS, et al. Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers. J Hosp Infec. 2019;101:42\u20136.","journal-title":"J Hosp Infec"},{"issue":"19","key":"446_CR16","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"B Cao","year":"2020","unstructured":"Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787\u201399.","journal-title":"N Engl J Med"},{"key":"446_CR17","doi-asserted-by":"crossref","first-page":"eaa13653","DOI":"10.1126\/scitranslmed.aal3653","volume":"9","author":"TP Sheahan","year":"2017","unstructured":"Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9:eaa13653.","journal-title":"Sci Transl Med"},{"key":"446_CR18","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1073\/pnas.1922083117","volume":"117","author":"E de Wit","year":"2020","unstructured":"de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci USA. 2020;117:6771\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"446_CR19","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","volume":"11","author":"TP Sheahan","year":"2020","unstructured":"Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11:222.","journal-title":"Nat Commun"},{"key":"446_CR20","doi-asserted-by":"crossref","unstructured":"20Jiang Y, Chen D, Cai D, Yi Y, Jiang S. Effectiveness of remdesivir for the treatment of hospitalized Covid-19 persons: a network meta-analysis. J Med Virol. 2020.","DOI":"10.1002\/jmv.26443"},{"key":"446_CR21","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/jmv.25798","volume":"92","author":"JS Khalili","year":"2020","unstructured":"Khalili JS, Zhu H, Mak NSA, Yan Y, Zhu Y. Novel coronavirus treatment with ribavirin: groundwork for evaluation concerning COVID-19. J Med Virol. 2020;92:740\u20136.","journal-title":"J Med Virol"},{"issue":"20","key":"446_CR22","first-page":"30534","volume":"S1201\u20139712","author":"S Arshad","year":"2020","unstructured":"Arshad S, Kilgore P, Chaudhry ZS, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis. 2020;S1201\u20139712(20):30534\u20138.","journal-title":"Int J Infect Dis"},{"key":"446_CR23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436","author":"The RECOVERY Collaborative Group","year":"2020","unstructured":"The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19\u2014preliminary report. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMoa2021436.","journal-title":"N Engl J Med"},{"issue":"7","key":"446_CR24","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/jmv.25801","volume":"92","author":"P Luo","year":"2020","unstructured":"Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. 2020;92(7):814\u20138.","journal-title":"J Med Virol"},{"issue":"7","key":"446_CR25","first-page":"489","volume":"21","author":"G Patti","year":"2020","unstructured":"Patti G, Lio V, Cavallari I, et al. Antithrombotic treatments in patients with SARS-CoV-2 infection: from current evidence to reasonable recommendations\u2014a position paper from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology. G Ital Cardiol (Rome). 2020;21(7):489\u2013501.","journal-title":"G Ital Cardiol (Rome)"},{"key":"446_CR26","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378:615\u201324.","journal-title":"N Engl J Med"},{"issue":"6","key":"446_CR27","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/jth.14871","volume":"18","author":"S Testa","year":"2020","unstructured":"Testa S, Prandoni P, Paoletti O, et al. Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: the Cremona experience. J Thromb Haemost. 2020;18(6):1320\u20133.","journal-title":"J Thromb Haemost"},{"key":"446_CR28","first-page":"39","volume":"3","author":"M Mahamid","year":"2011","unstructured":"Mahamid M, Mader R, Safadi R. Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions. Clin Pharmacol. 2011;3:39\u2013433.","journal-title":"Clin Pharmacol"},{"key":"446_CR29","first-page":"1023","volume":"14","author":"B Russell","year":"2020","unstructured":"Russell B, Moss C, Rigg A, Van Hemelrijck M. COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? Ecancermedicalscience. 2020;14:1023.","journal-title":"Ecancermedicalscience"},{"issue":"20","key":"446_CR30","first-page":"30673","volume":"S0002\u20139343","author":"PA McCullough","year":"2020","unstructured":"McCullough PA, Kelly RJ, Ruocco G, et al. Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) Infection. Am J Med. 2020;S0002\u20139343(20):30673\u201382.","journal-title":"Am J Med"},{"issue":"4","key":"446_CR31","doi-asserted-by":"crossref","first-page":"e25489","DOI":"10.1002\/jia2.25489","volume":"23","author":"N Ford","year":"2020","unstructured":"Ford N, Vitoria M, Rangaraj A, Norris SL, Calmy A, Doherty M. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment. J Int AIDS Soc. 2020;23(4):e25489.","journal-title":"J Int AIDS Soc"},{"key":"446_CR32","doi-asserted-by":"crossref","unstructured":"Singhania N, Bansal S, Nimmatoori DP, et al. Current overview on hypercoagulability in COVID-19. Am J Cardiovasc Drugs. 2020;1\u201311.","DOI":"10.1007\/s40256-020-00431-z"},{"issue":"23","key":"446_CR33","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1016\/j.jacc.2020.04.031","volume":"75","author":"B Bikdeli","year":"2020","unstructured":"Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020;75(23):2950\u201373.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"446_CR34","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1055\/s-0040-1710019","volume":"120","author":"Z Zhai","year":"2020","unstructured":"Zhai Z. Prevention and treatment of venous thromboembolism associated with coronavirus disease 2019 infection: a consensus statement before guidelines. Thromb Haemost. 2020;120(6):937\u201348.","journal-title":"Thromb Haemost"},{"key":"446_CR35","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1111\/j.1538-7836.2010.04044.x","volume":"8","author":"S Barbar","year":"2010","unstructured":"Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010;8:2450\u20137.","journal-title":"J Thromb Haemost"},{"key":"446_CR36","doi-asserted-by":"crossref","first-page":"e001152","DOI":"10.1161\/JAHA.114.001152","volume":"3","author":"D Rosenberg","year":"2014","unstructured":"Rosenberg D, Eichorn A, Alarcon M, McCullagh L, McGinn T, Spyropoulos AC. External validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for medical patients in a tertiary health system. J Am Heart Assoc. 2014;3:e001152.","journal-title":"J Am Heart Assoc"},{"key":"446_CR37","unstructured":"World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (2019nCoV) infection is suspected. Interim guidance. 2020. https:\/\/www.who.int\/publications-detail\/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed 31 July 2020."},{"issue":"5","key":"446_CR38","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/jth.14817","volume":"18","author":"N Tang","year":"2020","unstructured":"Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094\u20139.","journal-title":"J Thromb Haemost"},{"key":"446_CR39","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jacc.2020.05.001","volume":"76","author":"I Paranjpe","year":"2020","unstructured":"Paranjpe I, Fuster V, Lala A, Russak A, Glicksberg BS, Levin MA, Charney AW, Narula J, Fayad ZA, Bagiella E, Zhao S, Nadkarni GN. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol. 2020;76:122\u20134.","journal-title":"J Am Coll Cardiol"},{"key":"446_CR40","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054\u201362.","journal-title":"Lancet"},{"key":"446_CR41","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"SV Konstantinides","year":"2020","unstructured":"Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41:543\u2013603.","journal-title":"Eur Heart J"},{"key":"446_CR42","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.thromres.2020.04.011","volume":"190","author":"DC Rotzinger","year":"2020","unstructured":"Rotzinger DC, Beigelman-Aubry C, von Garnier C, Qanadli SD. Pulmonary embolism in patients with COVID-19: time to change the paradigm of computed tomography. Thromb Res. 2020;190:58\u20139.","journal-title":"Thromb Res"},{"key":"446_CR43","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1515\/cclm-2020-0198","volume":"58","author":"G Lippi","year":"2020","unstructured":"Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020;58:1131\u20134.","journal-title":"Clin Chem Lab Med"},{"key":"446_CR44","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1136\/heartjnl-2020-317322","volume":"106","author":"GG Stefanini","year":"2020","unstructured":"Stefanini GG, Chiarito M, Ferrante G, et al. Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19. Heart. 2020;106:1512\u20138.","journal-title":"Heart"},{"key":"446_CR45","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/jth.14768","volume":"18","author":"N Tang","year":"2020","unstructured":"Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844\u20137.","journal-title":"J Thromb Haemost"},{"key":"446_CR46","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1161\/CIRCULATIONAHA.120.046941","volume":"141","author":"KJ Clerkin","year":"2020","unstructured":"Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and cardiovascular disease. Circulation. 2020;141:1648\u201355.","journal-title":"Circulation"},{"key":"446_CR47","first-page":"1775","volume":"323","author":"G Onder","year":"2020","unstructured":"Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020;323:1775\u20136.","journal-title":"JAMA"},{"key":"446_CR48","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1056\/NEJMc2009166","volume":"383","author":"O De Filippo","year":"2020","unstructured":"De Filippo O, D\u2019Ascenzo F, Angelini F, et al. Reduced rate of hospital admissions for ACS during Covid-19 outbreak in Northern Italy. N Engl J Med. 2020;383:88\u20139.","journal-title":"N Engl J Med"},{"key":"446_CR49","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/heartjnl-2020-317056","volume":"106","author":"Y Kang","year":"2020","unstructured":"Kang Y, Chen T, Mui D. Cardiovascular manifestations and treatment considerations in covid-19. Heart. 2020;106:1132\u201341.","journal-title":"Heart"},{"key":"446_CR50","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1056\/NEJMoa1702090","volume":"378","author":"JC Kwong","year":"2018","unstructured":"Kwong JC, Schwartz KL, Campitelli MA, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med. 2018;378:2540\u20131.","journal-title":"N Engl J Med"},{"key":"446_CR51","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","volume":"40","author":"FJ Neumann","year":"2019","unstructured":"Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC\/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40:87\u2013165.","journal-title":"Eur Heart J"},{"key":"446_CR52","first-page":"332","volume":"21","author":"F Scotto di Uccio","year":"2020","unstructured":"Scotto di Uccio F, Valente S, Colivicchi F, et al. Position paper ANMCO: Organizzazione della Rete per il trattamento dei pazienti con sindrome coronarica acuta durante emergenza pandemica COVID-19. G Ital Cardiol. 2020;21:332\u20135.","journal-title":"G Ital Cardiol"},{"key":"446_CR53","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/j.jacc.2020.03.031","volume":"75","author":"E Driggin","year":"2020","unstructured":"Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol. 2020;75:2352\u201371.","journal-title":"J Am Coll Cardiol"},{"key":"446_CR54","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1001\/jamacardio.2020.0950","volume":"5","author":"S Shi","year":"2020","unstructured":"Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan. China. JAMA Cardiol. 2020;5:802\u201310.","journal-title":"China. JAMA Cardiol"},{"key":"446_CR55","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.120.047525","volume":"141","author":"GG Stefanini","year":"2020","unstructured":"Stefanini GG, Montorfano M, Trabattoni D, et al. ST-elevation myocardial infarction in patients with COVID-19: Clinical and angiographic outcomes. Circulation. 2020;141:2113\u20136.","journal-title":"Circulation"},{"key":"446_CR56","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1001\/jama.2020.13372","volume":"324","author":"S Bilaloglu","year":"2020","unstructured":"Bilaloglu S, Aphinyanaphongs Y, Jones S, et al. Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System. JAMA. 2020;324:799\u2013801.","journal-title":"JAMA"},{"key":"446_CR57","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.120.031011","author":"S Escalard","year":"2020","unstructured":"Escalard S, Chalumeau V, Escalard C, et al. Early brain imaging shows increased severity of acute ischemic strokes with large vessel occlusion in COVID-19 Patients. Stroke. 2020. https:\/\/doi.org\/10.1161\/STROKEAHA.120.031011.","journal-title":"Stroke"},{"key":"446_CR58","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1056\/NEJMc2007575","volume":"382","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020;382:e38.","journal-title":"N Engl J Med"},{"key":"446_CR59","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2141.2009.07600.x","volume":"145","author":"M Levi","year":"2009","unstructured":"Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol. 2009;145:24\u201333.","journal-title":"Br J Haematol"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-020-00446-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-020-00446-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-020-00446-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T15:58:32Z","timestamp":1606924712000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-020-00446-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,3]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["446"],"URL":"https:\/\/doi.org\/10.1007\/s40256-020-00446-6","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"type":"print","value":"1175-3277"},{"type":"electronic","value":"1179-187X"}],"subject":[],"published":{"date-parts":[[2020,11,3]]},"assertion":[{"value":"1 October 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Giuseppe Patti, Veronica Lio, Ilaria Cavallari, Felice Gragnano, Letizia Riva, Paolo Calabr\u00f2, Giuseppe Di Pasquale, Vittorio Pengo, and Andrea Rubboli declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Open access funding provided by Universit\u00e0 degli Studi del Piemonte Orientale Amedeo Avogrado within the CRUI-CARE Agreement. None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"GP: Lecture fee\/consultant\/advisory board for Amgen, Sanofi, Bayer, Boehringer Ingelheim, BMS-Pfizer, Daiichi Sankyo, Astra Zeneca, Sigma-Tau, Malesci, PIAM, and MSD. VL: None. IC: Lecture fee for Boehringer Ingelheim and BMS-Pfizer. FG: None. LR: Lecture fee\/consultant\/advisory board for Boehringer Ingelheim, Bayer, and Daiichi Sankyo. PC: Lecture fee\/consultant\/advisory board for Amgen, Sanofi, Bayer, Boehringer Ingelheim, BMS-Pfizer, Daiichi Sankyo, Astra Zeneca, and MSD. GDP: Lecture fee\/consultant\/advisory board for Boehringer Ingelheim, BMS-Pfizer, Bayer, and Daiichi Sankyo. VP: Lecture fee\/consultant\/advisory board for Bayer, Daiichi Sankyo, and Werfen Group. AR: Lecture fee\/consultant\/advisory board for Astra Zeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, and Pfizer-BMS.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}